aHUS Biomarker Proteins for Complement Inhibitor Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for atypical hemolytic uremic syndrome (aHUS) are limited, and there is a need for effective diagnosis, monitoring, and management of the disease, particularly in response to complement inhibitor therapy.
Innovation Solution
Monitoring and evaluating the concentration and activity of specific aHUS-associated biomarker proteins in biological fluids, such as serum and urine, to diagnose aHUS, assess treatment response, and determine optimal dosing of complement inhibitors like anti-C5 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma infusion or plasma exchange is used to treat aHUS, then treatment effect is achieved, but treatment complexity and risk increase
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (uncontrolled complement activation) from the complex disease process, using biomarkers to identify and monitor this specific pathway. This allows for targeted inhibition rather than broad plasma-based interventions, simplifying the treatment approach while maintaining effectiveness.
Solution Approach 2:
The patent uses biomarker parameter changes (concentration and activity levels of specific proteins) to guide treatment decisions. By monitoring these parameters, the treatment can be adjusted based on objective measurements of disease activity and response, replacing empirical plasma therapy with parameter-driven targeted therapy.
2Reliability
If complement inhibitor therapy is administered, then disease progression is controlled, but diagnostic accuracy and treatment monitoring capability are needed
Solution Approach 1:
The patent implements a feedback mechanism by measuring biomarker concentrations and activity levels before, during, and after complement inhibitor therapy. These measurements provide feedback on disease activity and treatment response, allowing for accurate diagnosis, monitoring of disease progression, and assessment of therapeutic efficacy.
Solution Approach 2:
The patent replaces empirical clinical assessment with objective biochemical measurements of biomarker concentrations and activities. This substitution provides more precise and quantifiable data for diagnosis and monitoring compared to traditional clinical evaluation methods.
3Measurement precision
If multiple biomarker proteins are monitored, then diagnostic and monitoring accuracy improves, but measurement complexity increases
Solution Approach 1:
The patent segments the complex biomarker analysis into distinct functional categories: concentration measurements and activity measurements. This segmentation allows for systematic evaluation of different aspects of biomarker status using appropriate measurement methods for each type, managing complexity through structured organization.
Solution Approach 2:
The patent establishes a universal biomarker panel that can be used across different clinical scenarios including diagnosis, disease progression monitoring, and treatment response assessment. This multi-functional biomarker system serves multiple purposes with a single standardized approach, reducing overall measurement complexity.
Data Source
AI summary
The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.